Healthcare / Pharmaceutical RetailersNSE
$874.65
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $3.7B · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$105.0B
P/E
49.0x
↑EV/EBITDA
17.3x
↑ROE
11.1%
↑Gross Margin
26.2%
↓Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+15.0%
FCF CAGR
—
FCF margin
5.4%
FCF / Net income
1.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $68.92B · net income $2.20B · FCF $3.73B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $68.92B | $68.92B | $61.36B | $55.74B | $45.29B |
| Net Income | $2.20B | $2.20B | $1.50B | $654.7M | $497.6M |
| EBITDA | $6.79B | $6.79B | $5.36B | $3.94B | $3.12B |
| EPS | 18.29 | 18.29 | 12.52 | 5.45 | 4.17 |
| Gross Margin | 26.2% | 26.2% | 24.4% | 21.2% | 21.4% |
| Operating Margin | 4.7% | 4.7% | 3.9% | 2.4% | 1.9% |
| Net Margin | 3.2% | 3.2% | 2.4% | 1.2% | 1.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.72 | 0.72 | 0.64 | 0.64 | 0.60 |
| Current Ratio | 3.00 | 3.00 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $3.73B | $3.73B | $4.81B | $593.4M | $-786.0M |
| Returns | |||||
| ROE | 11.1% | 11.1% | 8.6% | 4.1% | 3.3% |
| Valuation | |||||
| P/E | 49.03 | 49.03 | 58.32 | 126.88 | 157.11 |
| EV/EBITDA | 17.28 | 17.28 | 18.29 | 23.39 | 27.26 |
| P/B | 5.32 | 5.32 | 5.04 | 5.26 | 5.26 |
| Growth & Yield | |||||
| Revenue Growth | 12.3% | 12.3% | 10.1% | 23.1% | — |
| EPS Growth | 46.1% | 46.1% | 129.7% | 30.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
61.9%
EPS terminal req.
$77.61
Spread vs growth
-15.8%
5Y implied EPS CAGR
38.7%
EPS terminal req.
$93.91
Spread vs growth
7.4%
10Y implied EPS CAGR
23.5%
EPS terminal req.
$151.24
Spread vs growth
22.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.9%
Start / end P/E
75.8x → 47.8x
EPS bridge
12.52 → 18.29
Residual
-17.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.